Krystal Biotech, Inc. (KRYS)
347.00
+1.45
(+0.42%)
USD |
NASDAQ |
Sep 11, 16:00
346.79
-0.21
(-0.06%)
After-Hours: 20:00
Krystal Biotech Profit Margin (Quarterly) : 45.94% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 45.94% |
| March 31, 2026 | 48.07% |
| December 31, 2025 | 47.99% |
| September 30, 2025 | 81.15% |
| June 30, 2025 | 39.91% |
| March 31, 2025 | 40.52% |
| Date | Value |
|---|---|
| December 31, 2024 | 49.90% |
| September 30, 2024 | 32.42% |
| June 30, 2024 | 22.15% |
| March 31, 2024 | 2.06% |
| December 31, 2023 | 20.62% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 3.24% |
| Cytokinetics, Inc. | -694.4% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Exelixis, Inc. | 33.73% |
| Regeneron Pharmaceuticals, Inc. | 30.23% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.01% |
| Return on Assets | 18.27% |
| Return on Invested Capital | 19.86% |
| Gross Profit Margin (Quarterly) | 93.46% |
| Operating Margin (Quarterly) | 49.00% |
| Return on Net Operating Assets | 72.07% |